Close Menu

NEW YORK – Exact Sciences reported after the close of the market on Thursday that its second quarter revenues rose 35 percent year over year, despite a 34 percent decrease in screening product revenues.

For the three months ended June 30, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $268.9 million, up from $199.9 million a year earlier, beating the average Wall Street estimate of $228.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.